Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.05.

EBIT: As of FY2026 Q1, the actual value is USD -2.24 M.

BeyondSpring Inc. (万春药业) announced its financial results for the quarter ended March 31, 2026, as detailed in a press release furnished via a Form 8-K filing .

First Quarter 2026 Financial Results (Continuing Operations)

Research and Development (R&D) Expenses

For the three months ended March 31, 2026, R&D expenses were - $1.1 million, an increase of $0.2 million compared to - $0.9 million for the three months ended March 31, 2025 . This increase was primarily due to increased drug manufacturing activities for potential future study initiation, partially offset by lower regulatory filing advisory and personnel expenses .

General and Administrative (G&A) Expenses

G&A expenses for the three months ended March 31, 2026, were - $1.1 million, a decrease of $0.6 million from - $1.7 million for the three months ended March 31, 2025 . This decrease was mainly driven by lower personnel and legal advisory expenses .

Net Loss from Continuing Operations

BeyondSpring Inc. (万春药业) reported a net loss of - $2.4 million for the three months ended March 31, 2026, compared to a net loss of - $2.6 million for the three months ended March 31, 2025 . More precisely, the net loss from continuing operations was - $2,351 thousand for the three months ended March 31, 2026, versus - $2,584 thousand for the same period in 2025 .

Cash, Cash Equivalents, and Short-Term Investments

As of March 31, 2026, cash, cash equivalents, and short-term investments totaled $7.9 million . This included cash and cash equivalents of $4,036 thousand and short-term investments of $3,827 thousand .

First Quarter 2026 Financial Results (Discontinued Operations)

Net Loss from Discontinued Operations

For the three months ended March 31, 2026, net loss from discontinued operations was - $4.3 million . This contrasts with a net income of $3.8 million for the three months ended March 31, 2025, which included a $6,986 thousand gain on sale of subsidiary interests .

Current Assets of Discontinued Operations

As of March 31, 2026, current assets of discontinued operations were $5.3 million .

Additional Balance Sheet Metrics (as of March 31, 2026 vs. December 31, 2025)

Total Current Assets

Total current assets decreased to $13,504 thousand as of March 31, 2026, from $20,882 thousand as of December 31, 2025 .

Total Assets

Total assets were $18,406 thousand as of March 31, 2026, down from $25,933 thousand as of December 31, 2025 .

Accounts Payable

Accounts payable increased to $646 thousand as of March 31, 2026, from $363 thousand as of December 31, 2025 .

Accrued Expenses

Accrued expenses rose to $1,278 thousand as of March 31, 2026, from $938 thousand as of December 31, 2025 .

Current Liabilities of Discontinued Operations

Current liabilities of discontinued operations decreased to $9,263 thousand as of March 31, 2026, from $11,133 thousand as of December 31, 2025 .

Total Current Liabilities

Total current liabilities were $12,370 thousand as of March 31, 2026, compared to $13,576 thousand as of December 31, 2025 .

Deferred Revenue

Deferred revenue increased slightly to $28,994 thousand as of March 31, 2026, from $28,600 thousand as of December 31, 2025 .

Total Liabilities

Total liabilities decreased to $48,760 thousand as of March 31, 2026, from $49,923 thousand as of December 31, 2025 .

Accumulated Deficit

The accumulated deficit increased to - $410,590 thousand as of March 31, 2026, from - $408,431 thousand as of December 31, 2025 .

Total Shareholders’ Deficit

Total shareholders’ deficit worsened to - $30,354 thousand as of March 31, 2026, from - $23,990 thousand as of December 31, 2025 .

Additional Income Statement Metrics (Three months ended March 31, 2026 vs. 2025)

Revenue

BeyondSpring Inc. (万春药业) reported no revenue for both the three months ended March 31, 2026, and March 31, 2025 .

Loss from Operations

Loss from operations was - $2,232 thousand for the three months ended March 31, 2026, compared to - $2,610 thousand for the same period in 2025 .

Foreign Exchange Gain, net

Foreign exchange gain, net, was $50 thousand for the three months ended March 31, 2026, up from $29 thousand in the prior year period .

Interest Income

Interest income was $8 thousand for the three months ended March 31, 2026, down from $17 thousand in the prior year period .

Income Tax Expenses

Income tax expenses were - $192 thousand for the three months ended March 31, 2026, compared to - $20 thousand for the same period in 2025 .

Net Income (Loss) Attributable to BeyondSpring Inc.

Net loss attributable to BeyondSpring Inc. (万春药业) was - $2,159 thousand for the three months ended March 31, 2026, a decrease from a net income of $4,477 thousand for the same period in 2025 .

Comprehensive Income (Loss) Attributable to BeyondSpring Inc.

Comprehensive loss attributable to BeyondSpring Inc. (万春药业) was - $2,401 thousand for the three months ended March 31, 2026, compared to a comprehensive income of $4,380 thousand for the same period in 2025 .

Corporate Update and Outlook

BeyondSpring Inc. (万春药业) highlights Plinabulin’s potential as a foundational combination therapy to enhance efficacy and tolerability in ADC-based regimens, aiming to address limitations like durability and safety concerns . The company’s SEED Therapeutics division is advancing ST-01156, a novel molecular glue degrader, into Phase 1 clinical development using a biomarker-driven approach . These milestones reflect disciplined execution and position the company for long-term value through clinical and strategic partnership opportunities .